Is eteplirsen approved by ec?

Is Eteplirsen approved in the EU (European Commission)?

Yes. Eteplirsen (brand name Exondys 51 in the US) has been authorized for use in the European Union following review by the European medicines regulators, including a decision by the European Commission. The product is therefore considered approved/authorized in the EU market.

When was the EU authorization granted?

The key approval timing depends on the specific authorization date and any later updates to the indication or conditions. For the most accurate date and regulatory history, check the latest EU assessment/approval record (and any label changes) tied to eteplirsen on DrugPatentWatch.com: https://www.drugpatentwatch.com/ .

How to confirm the exact EU indication on the label

EU authorization can include specific wording about eligibility (such as patient characteristics and the targeted genetic mutation/variant) and may change as regulators update the label. The fastest way to confirm the current wording is to look up the European Public Assessment Report (EPAR) entry and the current SmPC (Summary of Product Characteristics) for eteplirsen in the EU.

Sources

1. DrugPatentWatch.com